Literature DB >> 12810182

Genes for asthma: much ado about nothing?

Paul A Whittaker1.   

Abstract

The identification of genes that make individuals susceptible to developing asthma is an area of increasing focus by both academic and industrial groups. The complexity of asthma genetics has made the identification of susceptibility genes difficult; however, genome-wide screens followed by positional cloning have started to identify such genes for both asthma and asthma-related traits. In addition, evidence from candidate gene studies indicates that gene-gene interactions also play an important role in conferring genetic risk for asthma development. Although progress in terms of identifying new therapeutic targets has not been dramatic, our understanding of the complexity of the genetic basis of asthma has greatly increased. There can be little doubt that, in the future, this knowledge will lead to fundamental insights into the molecular pathophysiology of asthma and the development of new therapies.

Entities:  

Mesh:

Year:  2003        PMID: 12810182     DOI: 10.1016/s1471-4892(03)00035-3

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

1.  A whole-genome scan for recurrent airway obstruction in Warmblood sport horses indicates two positional candidate regions.

Authors:  June E Swinburne; Helen Bogle; Jolanta Klukowska-Rötzler; Michaela Drögemüller; Tosso Leeb; Elizabeth Temperton; Gaudenz Dolf; Vincent Gerber
Journal:  Mamm Genome       Date:  2009-08       Impact factor: 2.957

Review 2.  RNA interference: from gene silencing to gene-specific therapeutics.

Authors:  Ray K M Leung; Paul A Whittaker
Journal:  Pharmacol Ther       Date:  2005-08       Impact factor: 12.310

3.  The Wheezing Illnesses Study Leidsche Rijn (WHISTLER): rationale and design.

Authors:  N Katier; C S P M Uiterwaal; B M de Jong; J L L Kimpen; T J Verheij; D E Grobbee; B Brunekreef; M E Numans; C K van der Ent
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.